Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22201730 | 0.87 | HRH4 (0.51) | HRH4HRH3HTR3AKDM4ERAD52 | |
| SCHEMBL568727 | 0.85 | HRH4 (0.50) | HRH4HRH3HTR3AKDM4ERAD52 | |
| SCHEMBL18704867 | 0.84 | PIK3CA (0.52) | LRRK2 | |
| SCHEMBL18500387 | 0.84 | ADRB1 (0.51) | HRH4HRH3 | |
| SCHEMBL10203431 | 0.83 | HRH4 (0.56) | HRH4HRH3HTR3AKDM4ERAD52 | |
| SCHEMBL13266581 | 0.77 | ALDH1A1 (0.45) | HRH4HRH3HTR3AKDM4EL3MBTL1 | |
| SCHEMBL12503866 | 0.76 | HRH4 (0.56) | HRH4HRH3HTR3AKDM4ERAD52 | |
| SCHEMBL21475674 | 0.76 | ADRB1 (0.47) | HRH4HRH3 | |
| SCHEMBL29676386 | 0.75 | HRH4 (0.44) | HRH4KDM4ERAD52UBE2NL3MBTL1 | |
| SCHEMBL16019498 | 0.75 | PANK3 (0.48) | HRH4HRH3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220315563-A1 | ALK-5 INHIBITORS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY, INC. | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315563-A1 | ALK-5 INHIBITORS AND USES THEREOF | ACVR1, ALK, ACVRL1 | HRH4 1515/4885HRH3 2119/4885HTR3A 2466/4885 |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | ACVR1, ALK, ACVRL1 | HRH4 1515/4885HRH3 2119/4885HTR3A 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.